GB0213383D0 - Therapeutic conditions - Google Patents

Therapeutic conditions

Info

Publication number
GB0213383D0
GB0213383D0 GBGB0213383.3A GB0213383A GB0213383D0 GB 0213383 D0 GB0213383 D0 GB 0213383D0 GB 0213383 A GB0213383 A GB 0213383A GB 0213383 D0 GB0213383 D0 GB 0213383D0
Authority
GB
United Kingdom
Prior art keywords
therapeutic conditions
therapeutic
conditions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB0213383.3A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Biotechnology Ltd
Original Assignee
Cambridge Biotechnology Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Biotechnology Ltd filed Critical Cambridge Biotechnology Ltd
Priority to GBGB0213383.3A priority Critical patent/GB0213383D0/en
Publication of GB0213383D0 publication Critical patent/GB0213383D0/en
Priority to AU2003240080A priority patent/AU2003240080A1/en
Priority to PCT/GB2003/002501 priority patent/WO2003103717A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB0213383.3A 2002-06-11 2002-06-11 Therapeutic conditions Ceased GB0213383D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GBGB0213383.3A GB0213383D0 (en) 2002-06-11 2002-06-11 Therapeutic conditions
AU2003240080A AU2003240080A1 (en) 2002-06-11 2003-06-11 Therapeutic conjugate consisting of a mek inhibitor and a targeting agent
PCT/GB2003/002501 WO2003103717A1 (en) 2002-06-11 2003-06-11 Therapeutic conjugate consisting of a mek inhibitor and a targeting agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0213383.3A GB0213383D0 (en) 2002-06-11 2002-06-11 Therapeutic conditions

Publications (1)

Publication Number Publication Date
GB0213383D0 true GB0213383D0 (en) 2002-07-24

Family

ID=9938360

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB0213383.3A Ceased GB0213383D0 (en) 2002-06-11 2002-06-11 Therapeutic conditions

Country Status (3)

Country Link
AU (1) AU2003240080A1 (en)
GB (1) GB0213383D0 (en)
WO (1) WO2003103717A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114788867A (en) * 2022-04-24 2022-07-26 天津医科大学总医院 Application of Map2k1 as therapeutic target of postchemotherapy neuralgia

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6510094A (en) * 1993-04-16 1994-11-08 University Of Portsmouth Enterprise Limited Drug delivery system
GB9721189D0 (en) * 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
WO2000056706A1 (en) * 1999-03-19 2000-09-28 Du Pont Pharmaceuticals Company Amino-thio-acrylonitriles as mek inhibitors
EP1165531A1 (en) * 1999-03-19 2002-01-02 Du Pont Pharmaceuticals Company N-adamant-1-yl-n'- 4-chlorobenzothiazol-2-yl] urea useful in the treatment of inflammation and as an anticancer radiosensitizing agent
GB9907429D0 (en) * 1999-03-31 1999-05-26 Microbiological Res Authority Modulation of C-fibre activity
AU6068600A (en) * 1999-07-16 2001-02-05 Warner-Lambert Company Method for treating chronic pain using mek inhibitors
AU8856201A (en) * 2000-09-01 2002-03-13 Andel Inst Van Inhibition of mitogen-activated protein kinase (mapk) pathway: a selective therapeutic strategy against melanoma

Also Published As

Publication number Publication date
WO2003103717A1 (en) 2003-12-18
AU2003240080A1 (en) 2003-12-22

Similar Documents

Publication Publication Date Title
GB0206876D0 (en) Therapeutic agents
GB0229931D0 (en) Therapeutic agents
GB0209991D0 (en) Therapeutic agents
GB0209997D0 (en) Therapeutic agents
GB0209995D0 (en) Therapeutic agents
GB0210127D0 (en) Therapeutic agents
GB0230087D0 (en) Therapeutic agents
GB0210124D0 (en) Therapeutic agents
GB0223349D0 (en) Therapeutic agents
GB0218526D0 (en) Combination therapy
AU2003215150A8 (en) Therapeutic compounds
GB0219660D0 (en) Therapeutic use
GB0218876D0 (en) Therapeutic agents
GB0225501D0 (en) Therapeutic agents
GB0217068D0 (en) Therapeutic agents
GB0226462D0 (en) Therapeutic agents
GB0208394D0 (en) Therapeutic agents
GB0208392D0 (en) Therapeutic compounds
AU2003231937A8 (en) Therapeutic methods
GB0213383D0 (en) Therapeutic conditions
GB0225399D0 (en) Therapeutic agents
GB0230027D0 (en) Therapy
GB0220841D0 (en) Therapy
GB0200134D0 (en) Therapeutic compounds
GB0201509D0 (en) Therapeutic Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)